In hematological malignancies, a combination of programmed cell death protein 1 blockade and CD19 CAR-T cell therapy in patients with B-ALL improves outcomes and CAR-T cell persistence [26]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.